[144] Quest Diagnostics Inc. SEC Filing

Rhea-AI Filing Summary

Quest Diagnostics (DGX) filed a Form 144 reporting a proposed sale of 1,903 common shares through Fidelity Brokerage Services (900 Salem Street, Smithfield, RI) with an approximate aggregate market value of $342,54008/15/2025. The filing lists total shares outstanding as 111,823,441. The document also discloses a recent sale by Thomas P. Plewman of 5,535 common shares on 08/06/2025 for gross proceeds of $968,625. The record of acquisition shows numerous small purchases and vesting events (ESPP purchases, dividend reinvestments, restricted stock vesting) between 02/01/2021 and 06/28/2024 that underlie the holdings to be sold.

Positive

• Transparent disclosure of proposed insider sale in compliance with Rule 144
• Detailed acquisition history showing shares were acquired via ESPP, dividend reinvestment, and restricted stock vesting

Negative

• Insider selling reported: proposed sale of 1,903 shares (aggregate value $342,540) and recent sale of 5,535 shares for $968,625

Insights

Securities Analyst

TL;DR: This Form 144 reports routine insider selling and prior recent sales; the amounts disclosed are modest relative to a large-cap issuer.

The filing notifies the market of a proposed sale of 1,903 common shares via Fidelity with an aggregate market value of $342,540 and records a recent sale of 5,535 shares by Thomas P. Plewman for $968,625. The acquisition history is composed mainly of ESPP purchases, dividend reinvestments, and periodic restricted stock vesting events, indicating routine compensation and employee share-purchase activity rather than a single large grant being monetized. From an investor-impact perspective, the filing is a disclosure of insider liquidity activity; it does not, by itself, provide evidence of material company-specific developments.

Corporate Governance Specialist

TL;DR: The notice shows compliance with Rule 144 disclosure for an insider sale and documents the provenance of shares through standard employee programs.

The Form 144 documents the seller's representation that no material nonpublic information exists and enumerates how the securities were acquired (ESPP, dividends, vesting). The granular acquisition schedule supports that the shares are and were acquired through customary compensation and purchase plans. No information in the filing indicates regulatory, governance, or control changes. This appears to be routine insider liquidity with appropriate disclosure filed.

08/15/2025 - 05:22 PM

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	1903	342540.00	111823441	08/15/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/01/2021	Dividend Reinvestment	Issuer			12	02/01/2021	Cash
Common	04/30/2021	ESPP Purchase	Issuer			18	04/30/2021	Cash
Common	05/28/2021	ESPP Purchase	Issuer			12	05/28/2021	Cash
Common	06/30/2021	ESPP Purchase	Issuer			12	06/30/2021	Cash
Common	07/19/2021	Dividend Reinvestment	Issuer			12	07/19/2021	Cash
Common	07/30/2021	ESPP Purchase	Issuer			11	07/30/2021	Cash
Common	09/30/2021	ESPP Purchase	Issuer			11	09/30/2021	Cash
Common	10/18/2021	Dividend Reinvestment	Issuer			12	10/18/2021	Cash
Common	10/29/2021	ESPP Purchase	Issuer			16	10/29/2021	Cash
Common	01/31/2022	Dividend Reinvestment	Issuer			12	01/31/2022	Cash
Common	02/17/2022	Restricted Stock Vesting	Issuer			210	02/17/2022	Compensation
Common	02/18/2022	Restricted Stock Vesting	Issuer			404	02/18/2022	Compensation
Common	02/28/2022	ESPP Purchase	Issuer			12	02/28/2022	Cash
Common	03/31/2022	ESPP Purchase	Issuer			12	03/31/2022	Cash
Common	04/18/2022	Dividend Reinvestment	Issuer			29	04/18/2022	Cash
Common	04/29/2022	ESPP Purchase	Issuer			18	04/29/2022	Cash
Common	05/31/2022	ESPP Purchase	Issuer			11	05/31/2022	Cash
Common	06/30/2022	ESPP Purchase	Issuer			12	06/30/2022	Cash
Common	07/18/2022	Dividend Reinvestment	Issuer			29	07/18/2022	Cash
Common	07/29/2022	ESPP Purchase	Issuer			12	07/29/2022	Cash
Common	10/31/2022	ESPP Purchase	Issuer			11	10/31/2022	Cash
Common	01/30/2023	Dividend Reinvestment	Issuer			27	01/30/2023	Cash
Common	02/18/2023	Restricted Stock Vesting	Issuer			319	02/18/2023	Compensation
Common	02/24/2023	Restricted Stock Vesting	Issuer			203	02/24/2023	Compensation
Common	02/28/2023	ESPP Purchase	Issuer			11	02/28/2023	Cash
Common	03/21/2023	Restricted Stock Vesting	Issuer			218	03/21/2023	Compensation
Common	03/31/2023	ESPP Purchase	Issuer			17	03/31/2023	Cash
Common	04/20/2023	Dividend Reinvestment	Issuer			44	04/20/2023	Cash
Common	04/28/2023	ESPP Purchase	Issuer			11	04/28/2023	Cash
Common	05/31/2023	ESPP Purchase	Issuer			12	05/31/2023	Cash
Common	06/30/2023	ESPP Purchase	Issuer			11	06/30/2023	Cash
Common	07/21/2023	Dividend Reinvestment	Issuer			44	07/21/2023	Cash
Common	07/31/2023	ESPP Purchase	Issuer			12	07/31/2023	Cash
Common	08/31/2023	ESPP Purchase	Issuer			12	08/31/2023	Cash
Common	11/30/2023	ESPP Purchase	Issuer			12	11/30/2023	Cash
Common	12/29/2023	ESPP Purchase	Issuer			11	12/29/2023	Cash
Common	03/28/2024	ESPP Purchase	Issuer			18	03/28/2024	Cash
Common	04/30/2024	ESPP Purchase	Issuer			11	04/30/2024	Cash
Common	05/31/2024	ESPP Purchase	Issuer			11	05/31/2024	Cash
Common	06/28/2024	ESPP Purchase	Issuer			11	06/28/2024	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Thomas P. Plewman 500 Plaza Drive Secaucus NJ 07094	Common	08/06/2025	5535	968625.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Quest Diagnostics' (DGX) Form 144 report?

The Form 144 reports a proposed sale of 1,903 common shares (approximate market value $342,540) with an approximate sale date of 08/15/2025.

Who conducted a recent sale reported in the filing?

The filing shows a recent sale by Thomas P. Plewman of 5,535 common shares on 08/06/2025 generating $968,625 in gross proceeds.

Through which broker will the proposed DGX shares be sold?

The proposed sale is to be executed through Fidelity Brokerage Services LLC (900 Salem Street, Smithfield, RI 02917).

What is the provenance of the shares to be sold?

The acquisition table shows shares were obtained via ESPP purchases, dividend reinvestment, and restricted stock vesting between 02/01/2021 and 06/28/2024.

How many Quest Diagnostics shares are outstanding per the filing?

The filing lists 111,823,441 shares outstanding.